X4 Pharmaceuticals (NASDAQ:XFOR) Share Price Breaks Below Fifty Day Moving Average – Here’s Why

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)’s share price crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.15 and traded as low as $2.98. X4 Pharmaceuticals shares last traded at $3.12, with a volume of 501,341 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 3rd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Stock Performance

The company has a market capitalization of $309.35 million, a PE ratio of -4.66 and a beta of 0.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.86 and a current ratio of 13.22. The stock’s fifty day simple moving average is $3.15 and its 200-day simple moving average is $3.77.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $2.88 million for the quarter, compared to analysts’ expectations of $2.78 million. X4 Pharmaceuticals had a negative net margin of 474.74% and a negative return on equity of 49.62%. As a group, equities analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

Insider Activity

In other news, CFO David Kirske sold 11,767 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total transaction of $33,653.62. Following the sale, the chief financial officer owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several large investors have recently added to or reduced their stakes in XFOR. Perceptive Advisors LLC grew its holdings in X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at about $917,000. Russell Investments Group Ltd. increased its stake in shares of X4 Pharmaceuticals by 2,871.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock valued at $618,000 after acquiring an additional 206,080 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of X4 Pharmaceuticals by 36.2% during the 3rd quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock worth $378,000 after acquiring an additional 34,698 shares during the period. Finally, WINTON GROUP Ltd lifted its holdings in shares of X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after acquiring an additional 3,800 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia.